Long-Term Efficacy of Evolocumab in Patients With or Without Multivessel Coronary Disease
Abstract
No abstract availableKeywords
Funding Information
- Amgen Inc
This publication has 19 references indexed in Scilit:
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated PatientsJAMA, 2016
- Interpretation of the evidence for the efficacy and safety of statin therapyThe Lancet, 2016
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular DiseaseNew England Journal of Medicine, 2016
- Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialAmerican Heart Journal, 2016
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- A Modified Poisson Regression Approach to Prospective Studies with Binary DataAmerican Journal of Epidemiology, 2004
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialThe Lancet, 2003
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995